The content on this site is intended for healthcare professionals only
Dr Ginah Nightingale speaks to ecancer at the SIOG 2019 meeting in Geneva about the prevalence and monitoring of drug-drug interactions (DDIs) in elderly cancer patients.
She mentions the high prevalence of DDIs, which may be attributed to polypharmacy, as these patients are prescribed numerous medications due to their increased co-morbidities.
Dr Nightingale describes a study which focuses on the prevalence of DDIs between proton-pump inhibitors which inhibit the absorption of tyrosine-kinase inhibitors, which are commonly prescribed to treat a variety of malignancies in older adults - leading to an increased risk of mortality.
She concludes by discussing what steps can be taken to reduce the prevalence of DDIs and the consequences of them in the clinic.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.
Powering equity in cancer care through digital health
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
OncoAlert Round Up for September 15-21, 2023
NSIA and BVGH aim to improve patient outcomes and access to quality cancer care
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
